Triclosan inhibit the growth of the late liver-stage of Plasmodium.
Annually, approximately two million human deaths are caused worldwide by malaria, most of them being children. Plasmodium falciparum is the leading cause of cerebral malaria, the most severe and fatal form of disease. Moreover, the emergence of resistant strains to the existing drugs has worsened the situation. Currently, primaquine is the only drug available for eliminating liver-stage parasites. Because of the emergence of resistant parasite strains, it becomes necessary to find new targets unique to the malaria parasites. In the Plasmodium species, the discovery of a distinct Type-II fatty-acid synthesis pathway has created an opportunity to target this pathway for the development of new inhibitors of malaria parasite growth. The present study explored the growth inhibition potential of triclosan in the case of liver-stage parasites. Liver-stage of Plasmodium is an excellent target for intervention due to very small parasite load as well as possibility of eliminating parasites before it can cause blood-stage infection. Here we report that triclosan inhibits the development of the Plasmodium liver-stage parasites.
Singh
Agam Prasad
AP
Infectious Diseases Laboratory (APS), Molecular Scicences Laboratory (AS), National Institute of Immunology, New Delhi, India. singhap@nii.res.in
Surolia
Namita
N
Surolia
Avadhesha
A
D000818:Animals; D002460:Cell Line; D006801:Humans; D008099:Liver / Q000469:parasitology*; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development; D014260:Triclosan / Q000494:pharmacology*
D014260:Triclosan